FDA Approves Dabrafenib Plus Trametinib for BRAF V600E–Mutated Unresectable or Metastatic Solid Tumors
EU-PEARL Webinar – Non-Concurrent Controls in Platform Trials Dr. Scott Berry and Dr. Kert Viele of Berry Consultants presented in the EU-PEARL webinar on February 24.